Since both tumor infiltrating mGPC1- CART and endogenous CD8+ T cells expressed PD-1, we also performed a combination therapy of mGPC1-CART and anti-PD-1 Ab in the MC38-mGPC1 model, and synergistic anti-tumor activities were shown without adverse effects. The gene discussed is RPL17; the disease is neoplasm.